Results 91 to 100 of about 2,094 (126)
Some of the next articles are maybe not open access.
Blood, 2000
AbstractRho(D) immune globulin intravenous (anti-D IGIV) was licensed by the United States Food and Drug Administration (FDA) in March 1995 to treat patients with immune thrombocytopenic purpura (ITP). Anti-D IGIV induces extravascular hemolysis, an expected adverse reaction that is consistent with the presumed mechanism of action.
exaly +3 more sources
AbstractRho(D) immune globulin intravenous (anti-D IGIV) was licensed by the United States Food and Drug Administration (FDA) in March 1995 to treat patients with immune thrombocytopenic purpura (ITP). Anti-D IGIV induces extravascular hemolysis, an expected adverse reaction that is consistent with the presumed mechanism of action.
exaly +3 more sources
Rho(D) immune globulin: A double blind clinical trial
American Journal of Obstetrics and Gynecology, 1970Morton A Stenchever, M A Stenchever
exaly +3 more sources
Rho (D) immune globulin in the emergency department
Journal of the American College of Emergency Physicians, 1975Many patients with spontaneous abortion receive definitive treatment in the emergency department. A part of treatment should include administration of Rh o (D) immune globulin (human) to patients who are Rh o (D) negative and Du negative (except when the husband is known to be Rh o (D) negative and Du negative).
openaire +1 more source
Postgraduate Medicine, 1984
PreviewTypically, Rho(D) immune globulin is used in Rho(D)-negative women after delivery of an Rho(D)-positive infant. However, there are other specific circumstances in which use of this agent, which has had a dramatic impact on the incidence of hemolytic disease in newborns, can prevent sensitization.
openaire +2 more sources
PreviewTypically, Rho(D) immune globulin is used in Rho(D)-negative women after delivery of an Rho(D)-positive infant. However, there are other specific circumstances in which use of this agent, which has had a dramatic impact on the incidence of hemolytic disease in newborns, can prevent sensitization.
openaire +2 more sources
Rho(D) immune globulin shortage and fetal Rh(D) screening with cell-free DNA
Current Opinion in Obstetrics & GynecologyPurpose of review Despite the availability of Rh(D) immune globulin (RhIg) to prevent alloimmunization in Rh(D)-negative pregnant patients, anti-Rh(D) alloimmunization remains a prevalent cause of hemolytic disease of the fetus and newborn (HDFN).
Matthew R, Grace +2 more
openaire +2 more sources
The Journal of Maternal-Fetal & Neonatal Medicine, 2007
This study evaluated the relationship between prenatal mercury exposure from thimerosal (49.55% mercury by weight)-containing Rho(D)-immune globulins (TCRs) and autism spectrum disorders (ASDs).The Institutional Review Board of the Institute for Chronic Illnesses approved the present study.
David A, Geier, Mark R, Geier
openaire +2 more sources
This study evaluated the relationship between prenatal mercury exposure from thimerosal (49.55% mercury by weight)-containing Rho(D)-immune globulins (TCRs) and autism spectrum disorders (ASDs).The Institutional Review Board of the Institute for Chronic Illnesses approved the present study.
David A, Geier, Mark R, Geier
openaire +2 more sources
Blood, 2006
In a recent issue of Blood, Gaines[1][1] reported on disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following intravenous administration of Rho(D) immune globulin as a treatment for immune thrombocytopenic purpura (ITP).
Joseph Schwartz +2 more
openaire +1 more source
In a recent issue of Blood, Gaines[1][1] reported on disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following intravenous administration of Rho(D) immune globulin as a treatment for immune thrombocytopenic purpura (ITP).
Joseph Schwartz +2 more
openaire +1 more source
Clinical evaluation of Rho(D) immune globulin (human) in Canada.
Canadian Medical Association journal, 1970-During 1966, clinical trials were conducted in three Canadian centres to determine the safety and efficacy of Rh(0)(D) immune globulin (human) in preventing isoimmunization by the Rh(0)(D) antigen in Rh-negative women delivering ABO-compatible Rh-positive infants.The candidates were randomly divided into control and treated groups; the treated mothers
E C, Bryant +6 more
openaire +1 more source
The Journal of reproductive medicine, 2003
To examine the practice patterns and differences between faculty members in obstetrics and gynecology (OB/G) and family practice (FP) residency programs in administering Rho(D) immune globulin (RhIG) for threatened abortion.A questionnaire was mailed to 50% (222) of all FP residencies and 100% (267) of OB/G programs in the United States.
Alicia M, Weissman +3 more
openaire +2 more sources
To examine the practice patterns and differences between faculty members in obstetrics and gynecology (OB/G) and family practice (FP) residency programs in administering Rho(D) immune globulin (RhIG) for threatened abortion.A questionnaire was mailed to 50% (222) of all FP residencies and 100% (267) of OB/G programs in the United States.
Alicia M, Weissman +3 more
openaire +2 more sources